Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ZKN
|
|||
| Former ID |
DCL000002
|
|||
| Drug Name |
PG-530742
|
|||
| Synonyms |
PG 116800; PG 530742; PGE 530742; PGE 7113313; PG-116800
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myocardial infarction [ICD-11: BA41-BA43] | Discontinued in Phase 2 | [1] | |
| Osteoarthritis [ICD-11: FA00-FA05] | Discontinued in Phase 2 | [1] | ||
| Company |
Pharmagenesis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H27N3O7S
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(=O)O
|
|||
| InChI |
1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)
|
|||
| InChIKey |
JAYVKNDQKXUNOJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 291533-11-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-3 (MMP-3) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | TNF signaling pathway | |||
| Transcriptional misregulation in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Panther Pathway | Plasminogen activating cascade | |||
| CCKR signaling map ST | ||||
| Pathway Interaction Database | Posttranslational regulation of adherens junction stability and dissassembly | |||
| p75(NTR)-mediated signaling | ||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| EGFR Transactivation by Gastrin | ||||
| WikiPathways | Activation of Matrix Metalloproteinases | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Oncostatin M Signaling Pathway | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. | |||
| REF 2 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.